Surgical menopause is the immediate, permanent loss of ovarian function caused by the surgical removal of both ovaries, a procedure called bilateral oophorectomy. Unlike natural menopause, which unfolds gradually over several years, surgical menopause happens overnight. Estrogen levels plummet within hours of surgery, triggering menopause regardless of how old you are at the time.
How It Differs From Natural Menopause
In natural menopause, your ovaries slowly wind down estrogen production over a transitional period that typically lasts four to eight years. Your body has time to adjust. In surgical menopause, that transition is eliminated entirely. One day your ovaries are functioning; the next day they’re gone. This abrupt hormonal shift is what makes surgical menopause more intense and, in many cases, more medically significant than natural menopause.
The sudden drop in estrogen produces more severe symptoms. Studies comparing the two groups find that women in surgical menopause report significantly higher rates of hot flashes, sweating, memory problems, and changes in sexual desire. These symptoms also tend to last longer. While natural menopause symptoms often peak and then gradually ease, surgical menopause symptoms can persist for years without treatment because the body has no remaining source of ovarian estrogen to taper from.
Why Ovaries Are Removed
The most common reasons for bilateral oophorectomy fall into two categories: treating existing disease or preventing future cancer. Women with serious endometriosis, ovarian cysts, or ovarian cancer may need their ovaries removed as part of treatment. On the prevention side, women who carry certain genetic mutations face substantially elevated risks of ovarian and fallopian tube cancer. Current guidelines recommend that women with BRCA1 mutations undergo preventive oophorectomy between ages 35 and 40, while women with BRCA2 mutations are advised to have the procedure before age 45.
Sometimes ovaries are removed during a hysterectomy even when there’s no ovarian disease, a practice that has become more controversial as research reveals the long-term health consequences of losing ovarian hormones early.
What Happens in Your Body
Your ovaries are your primary source of estrogen, and estrogen influences far more than your reproductive system. It plays a role in bone density, cardiovascular health, brain function, skin elasticity, vaginal tissue, and mood regulation. When both ovaries are removed, all of these systems feel the impact.
Research on the broader health effects paints a striking picture. Women who undergo surgical menopause before the natural age of menopause face higher rates of coronary heart disease, stroke, osteoporosis, cognitive impairment, Parkinson’s disease, and psychiatric disorders compared to women who keep their ovaries. Overall mortality is also higher: one large study found a rate of 16.8% in women who had their ovaries removed versus 13.3% in women whose ovaries were conserved. The younger you are at the time of surgery, the greater these risks tend to be.
Bone Loss Accelerates Quickly
Estrogen is essential for maintaining bone density, and surgical menopause triggers rapid bone loss. In the years immediately following oophorectomy, women can lose between 3.7% and 7.9% of spinal bone density per year. That’s a dramatic rate. After about five years, the pace of loss slows to roughly 1% per year, but by that point significant damage may already be done. Women in surgical menopause have notably higher rates of osteoporosis, particularly in the hip, compared to women who go through natural menopause.
Effects on the Brain
Some of the most consequential research on surgical menopause involves its effects on cognitive health. A landmark study from the Mayo Clinic found that women who had their ovaries removed before age 49 faced a 46% increased risk of cognitive impairment or dementia compared to women who retained their ovaries. The risk grew more pronounced the younger a woman was at surgery. Neuroimaging studies have also identified structural changes in brain regions associated with memory in women who underwent premenopausal oophorectomy, changes that may precede any noticeable symptoms of cognitive decline.
Critically, this increased dementia risk was not seen in women who were prescribed estrogen therapy at least until age 50. That finding has shaped how clinicians approach hormone therapy after surgical menopause.
Mood and Emotional Health
The hormonal crash of surgical menopause frequently affects mood. Anxiety, depression, and emotional volatility are common, and these symptoms are more rapid and severe than what most women experience during natural menopause. In one prospective study of 155 women undergoing gynecological surgery, 39% met criteria for depression before their procedure. By six months after surgery, that rate had dropped to about 22% in the surgical menopause group, likely reflecting recovery from the underlying disease that prompted surgery in the first place, along with adjustment over time.
Still, mood disruption after surgical menopause can be significant and should not be dismissed as a normal part of recovery. The sudden loss of estrogen directly affects brain chemistry, particularly the systems that regulate serotonin and other neurotransmitters involved in mood stability.
Sexual Health Changes
The sexual effects of surgical menopause are among the most disruptive to daily quality of life, yet they’re often underdiscussed. More than half of menopausal women experience symptoms of vaginal atrophy: dryness, burning, itching, and pain during intercourse. In surgical menopause, these changes arrive sooner and often more severely because of the steep estrogen drop.
Without estrogen, vaginal tissue becomes thinner and less elastic. The glands that produce natural lubrication become less active. The vaginal lining loses its protective barrier, making it more vulnerable to irritation and small tears. Over time, some women develop narrowing of the vaginal canal. Pain during sex leads to decreased desire, which leads to less frequent intercourse, which in turn reduces vaginal lubrication further, creating a cycle that can be difficult to break without intervention.
For mild to moderate symptoms, nonhormonal vaginal lubricants (used before intercourse) and vaginal moisturizers (used regularly, several times a week) are the standard first-line approach. When those aren’t enough, local estrogen therapy applied directly to vaginal tissue is highly effective, resolving symptoms in 80% to 90% of cases. This is generally preferred over systemic hormone therapy when vaginal dryness is the primary concern.
Hormone Therapy After Surgical Menopause
Hormone therapy plays a different role after surgical menopause than it does after natural menopause. For women who lose their ovaries before the typical age of menopause (around 51), replacing estrogen isn’t just about managing hot flashes. It’s about protecting bones, the brain, and the cardiovascular system from the consequences of decades without adequate estrogen.
Current guidelines recommend that women who undergo surgical menopause before age 40 or 45 receive hormone therapy regardless of whether they have noticeable symptoms. The goal is to continue therapy at least until the average age of natural menopause, effectively replacing what the ovaries would have provided. For women who had a hysterectomy along with oophorectomy, estrogen alone is typically sufficient. Women who still have a uterus need a combination of estrogen and a progestogen to protect the uterine lining.
There is no universally recommended cutoff for how long hormone therapy should continue. The prevailing view is that as long as the lowest effective dose is used and the woman is monitored regularly, there’s no reason to impose an arbitrary time limit. This is a significant shift from earlier decades, when hormone therapy was often stopped after a fixed number of years regardless of the patient’s individual risk profile.
The protective effect of estrogen therapy on the brain deserves emphasis. Research consistently shows that women who begin hormone therapy after surgical menopause and continue it until at least age 50 do not show the elevated dementia risk seen in untreated women. For women facing a decision about whether to start or continue hormone therapy, this is one of the most important pieces of the puzzle.